PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides. It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.
Earnings for PeptiDream Inc. (4587.T)
Earnings in 2023 (TTM): $31.26 M
According to PeptiDream Inc.'s latest financial reports the company's current earnings (TTM) are $31.26 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of PeptiDream Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $31.26 M | $20.15 M |
| 2022 | $44.15 M | $50.13 M |
| 2021 | $32.01 M | $23.93 M |
| 2020 | $39.95 M | $29.52 M |
| 2019 | $-9,377,737 | $-6,483,294 |
| 2018 | $25.26 M | $18.38 M |
| 2017 | $20.92 M | $15.5 M |
| 2016 | $17.41 M | $12.55 M |
| 2015 | $15.7 M | $10.49 M |
| 2014 | $9.91 M | $6.66 M |
| 2013 | $1.47 M | $985.59 K |
| 2012 | $1.16 M | $910.38 K |
| 2011 | $-143,001 | $66.17 K |